The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
- EMA Accepts Shionogi’s MAA for Ospemifene
April 1, 2013
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
- Takeda Files NDA for Fixed-Dose Combination of Takepron, Low-Dose Aspirin in Japan
March 29, 2013
- Takeda Files NDAs for Cell Culture-Based New Flu Vaccines
March 29, 2013
- Shionogi Settles Crestor Lawsuit in US
March 28, 2013
- Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey
March 28, 2013
- First Time NDA Filed in Japan for Meningococcal Vaccine: Sanofi
March 28, 2013
- Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
- AnGes Licenses Nucleic Acid Drug for Diseases Causing Lower Back Pain to Nippon Zoki in Japan
March 28, 2013
- Takeda, Novartis Rank 1st in Total Average Score with Favorable Impression on Quality of Development: IAL Survey
March 28, 2013
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…